Novo Holdings A/S

Novo Holdings A/S (formerly Novo A/S)[1] is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novonesis (formerly Novozymes A/S). Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which by the end of 2024 was worth €142 billion (approximately US$165 billion).[2] The company generated a total income and investment return of DKK 31 billion (€4.2 billion) in 2023[3] and DKK 60 billion (€8 billion) in 2024.[4][5][6] By the end of 2024, Novo Holdings had a total of 181 companies[5]

Purpose

Novo Holdings A/S manages the Novo Nordisk Foundation's assets, aiming to enable and make a positive impact on health, science and society by generating long-term returns on the assets of the Novo Nordisk Foundation, which the Novo Nordisk Foundation in return can award as grants for scientific research and humanitarian and social purposes.[11][12][13]

The overall purpose of Novo Holdings A/S is to hold the position as the controlling majority shareholder of the Novo Group companies (Novo Nordisk A/S and Novozymes A/S), aiming at making a positive impact on health, science and society by generating long-term returns on the assets of the Novo Nordisk Foundation.[14] The Novo Nordisk Foundation is an enterprise foundation which is a self-governing entity with no owners, focusing on long-term ownership of the Novo Group (Novo Nordisk A/S and Novozymes A/S) while combining business and philanthropy within scientific, humanitarian and social purposes. A key task of Novo Holdings A/S is to act as a stable basis for the commercial activities of Novo Nordisk A/S and Novozymes A/S. Novo Holdings A/S also invests in both financial assets and in companies with application-oriented research in the life sciences.

Objectives

Novo Holdings A/S' objective is to grow the assets of the Novo Nordisk Foundation. In addition to investing in equity and fixed income securities, Novo Holdings pursues direct investments in life science companies.[12] The Novo Nordisk Foundations share of financial returns generated from investments are added to the Novo Nordisk Foundation endowment and later distributed through charitable grants and awards aiming to improve the lives of people, science and society around the world.[12]

Novo Holdings A/S is recognised as a leading international life science investor focusing on creating long-term value.[11] Besides from being the controlling shareholder in the Novo Group companies (including Novo Nordisk A/S and Novozymes A/S),[15] Novo Holdings also provides seed and venture capital to companies in the development-stage.[13]

type	Private
key people	Kasim Kutay (CEO) Lars Rebien Sørensen (Chairman)
industry	Life sciences Asset management
assets	DKK 1,060 billion (2024) Approx. $161 billion (2024)
subsid	Novo Nordisk A/S Novozymes A/S
homepage	https://www.novoholdings.dk
foundation	1999
location city	Hellerup
location country	Denmark

Purpose

Objectives

Novo Group

Senior management

Board of directors

REPAIR Impact Fund

Investments

External links

References

Increased focus on industrial Biosolutions

Investment profile